Clinical trials
Early Alzheimer's Disease clinical trials
Below are recruiting early alzheimer's disease clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04150198Recruiting
PET-MR brain scan study of resilience in Alzheimer’s
This study uses a combined PET and MRI brain scan to understand why some people with Alzheimer’s (and related “focal” types) may cope better than expected. It may help researchers find brain patterns linked to resilience and to different Alzheimer’s subtypes.
OrsayAges 40–80 - NCT07741071RecruitingPhase 2
Vitamin B3 supplement for early Alzheimer's disease
This study tests whether a daily supplement (nicotinamide riboside, a form of vitamin B3) can slow the progression of early Alzheimer's disease over two years. It is a randomized, double-blind trial, meaning half the participants will get the supplement and half will get a placebo (a pill with no active ingredient), and neither you nor the doctors will know which you are getting.
BergenAges 50–85 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Irvine, CaliforniaAges 50–85 - NCT07688213RecruitingPhase 2
Study of an investigational drug for early Alzheimer's disease
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
The Villages, FloridaAges 55–85 - NCT06924359Recruiting
Eye scans and blood tests for early Alzheimer's detection
This study uses special eye scans and blood tests to find early signs of Alzheimer's disease. It aims to detect the disease before memory loss becomes severe, so treatment can start sooner.
BeijingAges 50 years+ - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT07153848Recruiting
Lecanemab treatment for early Alzheimer's disease
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Hangzhou, ZhejiangAges 45–85 - NCT07234942RecruitingPhase 1
Safety study of RO7812653 for early Alzheimer's disease
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
Toronto, OntarioAges 50–75 - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT02740634Recruiting
Brain imaging study for Alzheimer's disease
This study uses brain scans to understand Alzheimer's disease and related conditions that affect memory, language, or vision. It looks at how changes in the brain happen over time in people with these diagnoses.
Rochester, MinnesotaAges 21–80 - NCT07007208RecruitingPhase 2
Brain imaging study to detect early Alzheimer's risk
This study uses brain scans (MRI and PET) to look at a tiny brain region called the locus coeruleus, which may show early signs of Alzheimer's disease. Researchers want to see if changes in this area are linked to thinking skills and future memory decline.
ToulouseAges 60–100 - NCT07252440RecruitingPhase 2
Testing an oral drug for early Alzheimer's disease
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Chongqing, Chongqing MunicipalityAges 55–85 - NCT04123314RecruitingEarly Phase 1
Psilocybin study for depression in mild memory or early Alzheimer’s
This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.
Baltimore, MarylandAges 18–85 - NCT04575337Recruiting
Biomarker study to help detect Alzheimer’s early
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04661280RecruitingPhase 3
Donepezil compared with non-drug care for Alzheimer’s
This trial compares donepezil (a medicine for Alzheimer’s symptoms) against a non-drug treatment plan. It aims to see which approach helps people with Alzheimer’s who still have measurable thinking ability and specific Alzheimer’s test results.
ParisAges 50 years+ - NCT04804618Recruiting
Study uses blood protein changes in memory loss and Alzheimer’s
This trial studies blood “protein fingerprints” in people with mild memory problems or Alzheimer’s disease to better understand what’s happening. It may help researchers find ways to measure the condition and improve care over time.
Guangzhou, GuangdongAges 55 years+ - NCT05194787Recruiting
Online tests to spot early Alzheimer’s changes
This study looks at whether online motor (movement) and thinking tasks can detect early changes related to Alzheimer’s disease. You may be able to take part if you’re over 50 and do not already have a diagnosis of dementia.
Hobart, TasmaniaAges 50 years+ - NCT05315895Recruiting
Study of people with “dampness” signs in Chinese medicine
This is an observational study that looks at a Chinese-medicine pattern called “dampness” by collecting health and biological information from volunteers. It may help researchers better understand what this pattern looks like and how it relates to people’s health.
Guangzhou, GuangdongAges 35–79 - NCT05573490Recruiting
Lifestyle program study for early-onset Alzheimer’s
This study tests a structured lifestyle intervention to help people with early-onset Alzheimer’s disease. It is designed for adults with confirmed Alzheimer’s-related brain changes, and may help with symptoms or day-to-day functioning.
Indianapolis, IndianaAges 40–75 - NCT05655195Recruiting
At-home light and sound therapy for mild Alzheimer’s
This study tests whether regular at-home “gamma” light and sound stimulation can help people with mild Alzheimer’s. Participants start with a month at home and are followed to see how they do during treatment.
Cambridge, MassachusettsAges 65–100 - NCT05924425RecruitingPhase 4
Daridorexant for insomnia in early memory decline
This trial tests whether daridorexant can improve sleep in people who have mild cognitive impairment or early Alzheimer’s disease and struggle with insomnia. It may help by improving how long and how well you sleep, with monitoring of sleep patterns and memory-related measures.
MontpellierAges 60–85 - NCT06080659Recruiting
Brain network study for Alzheimer's and Parkinson's
This study uses brain scans to look for patterns that might help diagnose memory or movement problems like Alzheimer's or Parkinson's disease. It compares people with mild symptoms, like forgetfulness or early Parkinson's, to healthy volunteers.
RennesAges 50–80 - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80
Hear when a new Early Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early alzheimer's disease?
- Yes. Clin2 currently lists 109 recruiting early alzheimer's disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early alzheimer's disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early alzheimer's disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.